A heart transplant is an operation in which the diseased heart in a person is replaced with a healthy heart from a deceased donor. Ninety percent of heart transplants are performed on patients with end-stage heart failure.
Heart failure is a condition in which the heart is damaged or weakened and can't pump enough blood to meet the body's needs. "End-stage" means the condition has become so severe that all treatments, other than heart transplant, have failed.
A team has become the first in the US to reanimate the heart of a deceased donor and transplant it into a recipient.
Mayo Clinic's Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome (HLHS) and Children's of Alabama announce their collaboration within a consortium to provide solutions for patients with hypoplastic left heart syndrome, a rare and complex form of congenital heart disease in which the left side of the heart is severely underdeveloped.
In an analysis of the new heart organ allocation system for transplant patients in the U.S., researchers have identified a signal of a decrease in heart transplant survival rates.
Research into new endogenous mechanisms of tissue regeneration is an innovative research avenue in cardiac regeneration.
Nationally, heart failure patients who receive specialized cardiology care after admission tend to have better outcomes, including lower readmission rates and lower rates of death. But not all patients may have equal access to cardiology services.
Why don't patients with ventricular assist devices get better improvement in exercise tolerance? Increases in key internal heart pressures appear to be the answer, reports a study in the ASAIO Journal, official journal of ASAIO. The journal is published in the Lippincott portfolio by Wolters Kluwer.
There is a risk of every fourth heart examined for possible donation being dismissed as unusable due to stress-induced heart failure.
In March 2016, the Organ Procurement and Transplantation Network revised its criteria for prioritizing children awaiting heart transplantation in the U.S. with the intention of reducing the number of deaths on the waitlist, but a new study suggests unintended consequences.
The confluence of two major health crises—the opioid epidemic and organ shortage—has moved surgeons to consider transplanting organs deemed as less than "perfect" in an effort to expand the donor pool and save more lives, according to research published online today in The Annals of Thoracic Surgery, published by Elsevier.
In a major medical breakthrough, Tel Aviv University researchers have "printed" the world's first 3D vascularised engineered heart using a patient's own cells and biological materials.
Novel studies from around the world showing cutting-edge clinical use of cardiovascular magnetic resonance will be presented at EuroCMR 2019, a meeting of the European Association of Cardiovascular Imaging, a branch of the European Society of Cardiology.
Infectious diseases experts and transplant physicians and surgeons at Brigham and Women's Hospital have blocked the transmission of hepatitis C from infected organ donors to recipients in need of hearts or lungs.
A groundbreaking piece of medical technology was revealed to the public today at the National Research Center for Cardiac Surgery in Astana, Kazakhstan. At a press conference held at the Center, top heart failure experts from around the world announced the successful implantation of FIVAD into a human.
In a study published in iScience, Professor Akiyoshi Fukamizu of the Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (University of Tsukuba, JAPAN) and the research group reported a new work on discovery of the important role of PRMT1 in dilated cardiomyopathy.
Experts at the Vanderbilt Heart and Vascular Institute are forging new ground in the development of a first-of-its-kind program aimed at adults with congenital heart disease.
Experts from the world's major heart surgery organizations-including The Society of Thoracic Surgeons, the American Association for Thoracic Surgery, the Asian Society for Cardiovascular and Thoracic Surgery, and the European Association for Cardio-Thoracic Surgery-are calling for urgent action to develop and implement effective strategies for treating rheumatic heart disease, which affects 33 million people and kills 320,000 annually.
A Smidt Heart Institute patient is the first in the country to receive a new device to fix a leaky heart valve.
The new journal Cardiovascular Innovations and Applications has just published the first issue of Volume 3. This is a Special Issue on Adult Congenital Heart Disease with Guest Editor Diego Moguillansky of the University of Florida Medical School.
The University of Minnesota is the first institution in the state to participate in the phase III clinical trial for CardiAmp Therapy. Previous clinical studies of this therapy have been promising and have shown improvements in patients' quality of life and heart function.
Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with heart failure.